The Gln-Arg192 polymorphism of human paraoxonase gene is not associated with coronary artery disease in Italian patients

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 18, Issue 10, 1998, Pages 1611-1616

  Ombres, Domenico ^a   Pannitteri, Gaetano ^a   Montali, Anna ^a   Candeloro, Antonio ^a   Seccareccia, Fulvia ^b   Campagna, Filomena ^a   Cantini, Renzo ^a   Campa, Pietro Paolo ^a   Ricci, Giorgio ^a   Area, Marcello ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Coronary artery disease; Genetics; LDL oxidation; Myocardial infarction; Paraoxonase

Indexed keywords

ARYLESTERASE;

ALLELE; ANGIOCARDIOGRAPHY; ARTICLE; CORONARY ARTERY DISEASE; CORONARY RISK; DISEASE ASSOCIATION; FEMALE; GENETIC MARKER; GENETIC POLYMORPHISM; GENOTYPE; HEART INFARCTION; HUMAN; ITALY; LIPID OXIDATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCHOOL CHILD;

EID: 17344369707     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.18.10.1611     Document Type: Article

References (30)

1. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol: modifications of low density lipoprotein that increase its atherogenicity. N Engl J Med. 1989;320:915-924.
2. Berliner JA, Haberland ME. Role of oxidized low density lipoprotein in atherogenesis. Curr Opin Lipidol. 1991;4:373-381.
3. Mackness MI, Mackness B, Durrington PN, Connelly PW, Hegele A. Paraoxonase: biochemistry, genetics and relationship to plasma lipoprotein. Curr Opin Lipidol. 1996;7:69-76.
4. Mackness MI, Durrington PN. HDL, its enzymes and its potential to influence lipid peroxidation. Atherosclerosis. 1995;115:243-253.
5. Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett. 1991:286:152-154.
6. Mackness MI, Arrol S, Abbot CA, Durrington PN. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis. 1993;104:129-135.
7. Mueller RF, Horning S, Furlong OE, Anderson J, Giblett ER, Motulsky A. Plasma paraoxonase polymorphism: a new enzyme assay, population, family, biochemical and linkage studies. Am J Hum Genet. 1983;35:393-405.
8. Adkins S, Gan KN, Mody M, La Du BN. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet. 1993;52:598-608.
9. Humbert R, Adler DA, Disteche CM, Hasset C, Omiecinski CJ, Furlong CE. The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet. 1993;3:73-76.
10. Serrato M, Marian AJ. A variant of a human paraoxonase arylesterase (HUMPONA) gene is a risk factor for coronary artery disease. J Clin Invest. 1995;96:3005-3008.
11. Ruiz J, Blanché H, James RW, Garin MCB, Vaisse C, Charpentier G, Cohen N, Morabia A, Passa P, Froguel P. Gin-Arg 192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet. 1995;346:869-872.
12. Antikainen M, Murtomaki S, Syvanne M, Pahlman R, Tahvanainen E, Jauhiainen M, Frick MH, Ehnholm C. The Gln-Arg 192 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with the risk of coronary artery disease in Finns. J Clin Invest. 1996;98:883-885.
13. Austen WG, Edwards JE, Frye RL, Gensini GG, Gott VL, Griffith LS, McGoon DC, Murphy ML, Roe BB. A reporting system on patients evaluated for coronary artery disease: report of the Ad Hoc Committee for Grading of Coronary Artery Disease, Council on Cardiovascular Surgery, American Heart Association. Circulation. 1975;51(suppl 4):5-40.
14. Braunwald E. Heart Disease. 3rd ed. Philadelphia, Pa: WB Saunders; 1988.
15. Rose GA, Blackburn H. Cardiovascular Survey Methods. 1st ed. Geneva, Switzerland: World Health Organization; 1968. No. 56.
16. Rose GA, Hamilton PJS, Keen H, Reid DD, McCartney P, Jarrett RJ. Myocardial ischemia, risk factors and death from coronary heart disease. Lancet. 1977;1:105-109.
17. Miller SA, Dykes DD, Polesky HF. A simple salling-out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16:1215.
18. Lee JS. Alternative dideoxy sequencing of double-stranded DNA by cyclic reaction using Taq polymerase. DNA Cell Biol. 1991;10:67-73.
19. Lipid, and lipoprotein analysis. Manual of Laboratory Operations. Washington, DC: Lipid Research Clinics Program; 1984. US Dept of Health, Education, and Welfare 1. Publication NIH F5-628.
20. Arca M, Vega GL, Grundy SM. Hypercholesterolemia in post-menopausal women: metabolic defects and response to low-dose lovastatin. JAMA. 1994;271:453-459.
21. Montali A, Vega GL, Grundy SM. Concentration of apolipoprotein AI-containing particles in patients with hypoalphalipoproteinemia. Arterioscler Thromb. 1994;14:511-517.
22. Schlesselmann JJ. Case Control Studies: Design, Conduct and Analysis. New York, NY: Oxford University Press; 1982.
23. Hegele RA, Brunt JH, Connelly PW. A polymorphism of the paraoxonase gene associated with variation in plasma lipoproteins in a genetic isolate. Arterioscler Thromb Vasc Biol. 1995;15:89-95.
24. Harats D, Ben Naim M, Dabach Y, Hollander G, Stein O, Stein Y. Cigarette smoking renders LDL susceptible to peroxidative modification and enhanced metabolism by macrophages. Atherosclerosis. 1989;79:245-252.
25. Baynes J. Role of oxidative stress in development of complications in diabetes. Diabetes. 1991;40:405-412.
26. Lander ES, Schork NJ. Genetic dissection of complex traits. Science. 1994;266:353-354.
27. Marshall HW, Morrison LC, Wu LL, Anderson JL, Cornell PS, Stauffer DM, Allen A, Karagounis LA, Ward RH. Apolipoprotein polymorphism fail to define risk of coronary artery disease: results from a prospective, angiographically controlled study. Circulation. 1994;89:567-577.
28. Mackness MI, Arrol S, Mackness B, Durrington PN. Alloenzymes of paraoxonase and effectiveness of high-density lipoproteins in protecting low-density lipoprotein against lipid peroxidation. Lancet. 1997;359:851-852.
29. Garin MCB, James RW, Dussoix P, Blanchè H, Passa P, Froguel P, Ruiz J. Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme: a possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. J Clin Invest. 1997;99:62-66.
30. Bonanome A, Pagnan A, Biffanti S, Opportino A, Sorgato S, Dorella M, Maiorino M, Ursini F. Effect of dietary monouhsaturated and polyunsaturated fatty acids on the susceptibility of plasma low density lipoproteins to oxidative modification. Arterioscler Thromb. 1992;12:529-533.